medscape.com
Cure8 news brief
Why This Matters
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier use of advanced therapies, which may improve fistula healing and quality of life.
Who Should Pay Attention
Adults with Crohn's disease and perianal fistulas, patients on or considering biologic/JAK therapies, gastroenterologists, colorectal surgeons, and IBD care teams.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
Perianal fistulizing Crohn's is complex and typically needs coordinated medical and surgical care. Imaging (pelvic MRI or endoanal ultrasound) is used to define fistula anatomy and guide treatment.
Early use of effective advanced therapies is supported by AGA guidance for moderate-to-severe Crohn's and is recommended by the author for many patients with perianal disease. Anti‑TNF agents (infliximab, adalimumab) remain first-line with higher serum targets associated with better healing; antibiotics are sometimes used with biologics for induction.
Newer options such as IL‑23 blockade (guselkumab) and JAK inhibition (upadacitinib) are discussed as expanding choices, and recent trial data for guselkumab (FUZION) showed improved combined fistula remission versus placebo in a trial population.
Practical points include prompt drainage of sepsis/abscesses, seton placement/management, multidisciplinary coordination with surgeons and radiology, and individualized therapy selection based on anatomy and prior treatment response.
Keep In Mind
The article is an expert review summarizing guideline recommendations and emerging trial data (including the phase 3 FUZION guselkumab results). It is not a systematic review or new primary study; treatment decisions should be individualized and made with clinicians. Therapeutic-drug-monitoring targets cited are based on practice experience and studies referenced by the author.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedscape.com
PublisherMedscape
AuthorsDavid A. Schwartz, MD
Indexed viaGoogle News
Source typeWeb article
PublishedOct 8, 2026, 3:15 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Escalating Crohn’s Care: The Case for Dual Therapy
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
Escalating Crohn's Care: The Case for Dual Therapy - Medscape
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...